Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

India’s Department of Science & Technology announced last month that its scientists have developed a surface-modified solid lipid nanoparticle (SLN) visceral leishmaniasis therapy.

According to a July study in Nature Scientific Reports, the preparation (containing both amphotericin B and paromomycin) demonstrated enhanced anti-leishmanial activity in infected mice, with reduced toxicity compared to conventional oral therapies.


The Drugs for Neglected Diseases initiative (DNDi) and Novartis announced yesterday that they have agreed to jointly develop LXE408, a first-in-class compound discovered by Novartis, with financial support from the Wellcome Trust, as a potential new oral treatment for visceral leishmaniasis.

Under the terms of the deal, Novartis will be responsible for Phase 1 trials, regulatory submissions, and “affordable” distribution of the drug. DNDi will lead Phase 2 and 3 development, with the…

Britain allocated $274 million in funding this week to provide 600 million treatments against lymphatic filariasis, onchocerciasis, schistosomiasis, visceral leishmaniasis and trachoma.

A Department for International Development press release said the support was a “vital step” towards eliminating neglected tropical diseases (NTDs), including the specific goal to rid Asia of visceral leishmaniasis by 2022.

The funds are part of Britain’s 2017 pledge of almost $450 million to…


The Drugs for Neglected Diseases initiative (DNDi) announced progress on several product development initiatives this week.

Firstly, results from a Phase 2/3 trial in Malaysia and Thailand demonstrated that DNDi’s ravidasvir and sofosbuvir combination hepatitis C regimen cured 97 percent of participants. DNDi said in a press release that the $300 price tag of the drug manufactured by Egypt’s Pharco Pharmaceuticals is a fraction of existing treatment prices in Malaysia.


Britain has pledged $460 million over the next five years to combat neglected tropical diseases, the Department for International Development (DFID) announced this week. The investment, which more than doubles the country’s annual spending on NTDs, will support existing efforts to wipe out Guinea worm, help eliminate visceral leishmaniasis in Asia, prevent up to 400,000 cases of blindness caused by trachoma, and prevent “tens of thousands of cases of disability” caused by lymphatic…